Abstract
MicroRNAs (miRNAs) are a group of small noncoding RNAs capable of regulating specific gene expression. Let-7 miRNA was first discovered in Caenorhabditis elegans and it is highly conserved in human tissues. The human let- 7 family of miRNA contains 12 members of miRNA. Today, these members have become the most studied miRNAs and they have attracted attention of researchers in various fields, such as development, stem cell biology, aging, and metabolism. Furthermore, there is a large body of evidence linking the loss of let-7 expression and the development of poorly differentiated, aggressive cancers. In addition to the canonical biogenesis pathway, let-7 has been found to be regulated by protein factors, such as RNA binding proteins previously identified as regulators of protein-coding mRNAs. Moreover, the direct interaction between miRNAs has recently been identified as a novel pathway to control let-7 expression. In this review, we discuss the multifaceted roles of let-7 and provide an overview of its regulation at multiple levels.
Keywords: Embryo, Let-7, microRNA Biogenesis, noncoding RNAs, oncogenesis, phenotype, Caenorhabditis elegans, embryo, cytoplasm, chromosomal, malignancies.
MicroRNA
Title:Function and Regulation of Let-7 Family microRNAs
Volume: 1 Issue: 1
Author(s): Jen-Liang Su, Pai-Sheng Chen, Gunnar Johansson and Min-Liang Kuo
Affiliation:
Keywords: Embryo, Let-7, microRNA Biogenesis, noncoding RNAs, oncogenesis, phenotype, Caenorhabditis elegans, embryo, cytoplasm, chromosomal, malignancies.
Abstract: MicroRNAs (miRNAs) are a group of small noncoding RNAs capable of regulating specific gene expression. Let-7 miRNA was first discovered in Caenorhabditis elegans and it is highly conserved in human tissues. The human let- 7 family of miRNA contains 12 members of miRNA. Today, these members have become the most studied miRNAs and they have attracted attention of researchers in various fields, such as development, stem cell biology, aging, and metabolism. Furthermore, there is a large body of evidence linking the loss of let-7 expression and the development of poorly differentiated, aggressive cancers. In addition to the canonical biogenesis pathway, let-7 has been found to be regulated by protein factors, such as RNA binding proteins previously identified as regulators of protein-coding mRNAs. Moreover, the direct interaction between miRNAs has recently been identified as a novel pathway to control let-7 expression. In this review, we discuss the multifaceted roles of let-7 and provide an overview of its regulation at multiple levels.
Export Options
About this article
Cite this article as:
Su Jen-Liang, Chen Pai-Sheng, Johansson Gunnar and Kuo Min-Liang, Function and Regulation of Let-7 Family microRNAs, MicroRNA 2012; 1 (1) . https://dx.doi.org/10.2174/2211536611201010034
DOI https://dx.doi.org/10.2174/2211536611201010034 |
Print ISSN 2211-5366 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5374 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Using Insights into Pim1 Structure to Design New Anticancer Drugs
Current Pharmaceutical Design Doxorubicin Sensitizes the Non-Small Cell Lung Cancer Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated (TRAIL) Apoptosis In Vitro but not In Vivo
Letters in Drug Design & Discovery Brachytherapy: State of the Art and Possible Improvements
Anti-Cancer Agents in Medicinal Chemistry Suppression of Cancer Invasiveness by Dietary Compounds
Mini-Reviews in Medicinal Chemistry Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside
Current Molecular Medicine Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein
Current Medicinal Chemistry Development of Hedgehog Pathway Inhibitors (HPI) in Treatment of Cancer
Current Chemical Biology Innovations and Opportunities to Improve Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer
Current Medicinal Chemistry Patents and the Development on Polymer based Nanomaterial (PAMAM Dendrimer) for Biomedical Applications
Recent Patents on Biomedical Engineering (Discontinued) Targeting Angiogenesis in Renal Cell Carcinoma
Current Cancer Drug Targets Radioiodinated Agents for Imaging Multidrug Resistant Tumors
Medicinal Chemistry PET/CT Based Dose Planning in Radiotherapy
Current Medical Imaging It Takes Two to Tango: The Structure and Function of LIM, RING, PHD and MYND Domains
Current Pharmaceutical Design Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine
Current Drug Metabolism Use of Anticancer Platinum Compounds in Combination Therapies and Challenges in Drug Delivery
Current Medicinal Chemistry Immunossupressant and Organ Transplantation: Immunophilins Targeting Agent and Alternative Therapies
Current Medicinal Chemistry Effect of Doxycycline on Atherosclerosis: From Bench to Bedside
Recent Patents on Cardiovascular Drug Discovery Quantifying Gp96/Grp94 Complexes Preparations for Vaccines: a Key Step Often Inaccurate
Current Medicinal Chemistry Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery Indole-based, Antiproliferative Agents Targeting Tubulin Polymerization
Current Topics in Medicinal Chemistry